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INTRODUCTION
The tonsil is the most common oropharyngeal site of head and 
neck squamous cell carcinoma (SCC). Tonsil SCC mainly affects 
40 to 60 year olds, and appears to be strongly associated with 
alcohol, cigarette smoking, and human papillomavirus. The clini-
cal course of tonsil SCC is known to be aggressive, with frequent 
local or regional recurrence, and early dissemination. In fact, 60 
to 80% of tonsil SCC patients have cervical lymph node metas-
tasis at initial diagnosis. Surgery or radiation therapy alone is 
used to treat early tumors, whereas combined therapy is used 
for advanced tumors. However, it is difficult to determine the 
characteristics of tumors by TNM staging alone, and therefore, 
treatment modality selection and predicting prognosis are prob-
lematic. Accordingly, if a reliable method was devised to predict 
prognosis, cases with a poor prognosis could be aggressively trea-
ted, which would influence treatment success rates in this pati-
ent population (1).
 The matrix metalloproteinases (MMPs) are a family of zinc-
dependent endopeptidases, proteolytic enzymes that can de-
compose extracellular matrix components, like collagen, gelatin, 
elastin, fibronectin, and the proteoglycans. They also breakdown 
basement membranes around transformed keratinocytes and 
vessel or lymphatic duct epithelium, and thus, help tumor local 
invasion and metastasis. Several previous studies have conclud-
Objectives. To investigate expressions of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TI-
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Methods. Paraffin blocks were obtained from 45 tonsil squamous cell carcinoma (SCC) patients, who underwent surgery as 
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findings suggest that MMP-9 expression might be a useful prognostic factor.
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ed that the MMPs play an important role during the course of 
head and neck SCC. However, the nature of their roles in each 
head and neck primary site remains unresolved due to method-
ological differences between studies in terms of MMP detection 
and the relatively small sample sizes used. Tonsil SCC is charac-
terized by a rapid rate of local growth and a high propensity of 
early nodal metastasis, and therefore, it is expected that the roles 
played by MMPs may be important for tonsil SCC progression. 
However, no study has been performed on the role of MMPs in 
tonsil SCC (2, 3).
 In this study, we studied the expressions of MMP-2, 9, 13 and 
of their inhibitors tissue inhibitors of metalloproteinase (TIMP)-
1 and 2 in patients with tonsil SCC that underwent surgery as 
an initial treatment, and we searched for correlations between 
these expressions and clinical features, which including stage and 
treatment outcome. We also investigated whether these MMPs 
and TIMPs predict the course and prognosis of SCC of the ton-
sils.
MATERIALS AND METHODS
Selection of patients and tissue samples
Forty-five patients diagnosed as tonsil SCC and that underwent 
surgery as primary treatment between September 1994 and 
Mar ch 2004, with available paraffin blocks were recruited. The 
patients consisted of 41 males and 4 females, with a mean age 
of 56.6 years (range, 32 to 78 years) and smoking history was 
fo und in 38 patients (84.4%). Of these 45 patients, 9 received 
only surgical treatment, and 36 underwent surgery and postop-
erative radiotherapy. Follow-up periods ranged from 10 to 152 
months (average 74.1 months), and 44 of the 45 patients were 
followed. Disease stages were evaluated using the AJCC TNM 
system (2002). In the 45 cases stages were distributed as follows: 
9 patients were of T1, 27 of T2, 7 of T3, 2 of T4, 12 of N0, 6 of 
N1, 25 of N2, and 2 were of N3. The control group was compo-
sed of 20 healthy age and gender matched individuals who un-
derwent tonsillectomy due to chronic follicular tonsillitis.
Immunohistochemical staining
Paraffin-embedded tissue blocks were sectioned at 4-5 μm, moun-
ted on superfrost glass slides, deparaffinized with xylene, and 
rehydrated in a graded ethanol series. Endogenous peroxidase 
activity was inactivated by incubating slides for 10 minutes in 
0.3% hydrogen peroxide in methanol. After rinsing sections in 
Tris buffered saline, non-specific binding was blocked by incuba-
tion with goat serum for 30 minutes. Tissue sections were then 
incubated with the primary antibodies for: MMP-2 Ab-4 (Mono-
clonal, Clone A-Gel VC2), MMP-9 Ab-9 (Polyclonal), MMP-13 
Ab-1 (Monoclonal, Clone VIIIA2), TIMP-1 Ab-5 (Polyclonal), 
TIMP-2 Ab-5 (Monoclonal, Clone 3a4) (all were purchased from 
Neomarkers, Fremont, CA, USA) for 2 hours at room tempera-
ture. After incubation with biotinylated secondary antibodies 
(Zymed Co., South San Francisco, CA, USA), sections were in-
cubated with avidin-biotinylated peroxidase complex for 20 mi-
nutes at room temperature. Antigen visualization was achieved 
using 3-amino-9-ethyl carbazole (AEC), and counter staining 
was performed using Mayer’s hematoxylin.
Interpretation
Optical microscopic examinations (×400) were performed at 3 
sites per section with high tumor cell densities and showing lo-
cal invasiveness as determined by two pathologists. It was regard-
ed as positive reaction when more than 10% of tumor cells have 
brownish granules in the cytoplasm or when stroma is stained 
brownish.
Statistical analysis
Data were analyzed using SPSS ver. 11.0 (SPSS Inc., Chicago, 
IL, USA). The chi-square test and Spearman’s correlational anal-
ysis were used to investigate the association between immuno-
histochemical staining findings and clinical data. Survival was 
estimated using the Kaplan-Meier method, and the differences 
between curves were assessed with the log-rank test. Cox’s re-
gression test was used to identify factors that influence survival. 
Statistical significance was defined as P<0.05.
RESULTS
Expression patterns of MMPs and TIMPs
The expression patterns of MMPs and TIMPs as determined by 
immunohistochemical staining are summarized in Table 1. MMP-
2, MMP-13, TIMP-1, and TIMP-2 were detected in tumor cells 
and/or stroma, whereas MMP-9 was detected in tumor cells alone 
(Fig. 1). The expression rates of MMP-9, MMP-13, TIMP-1, and 
TIMP-2 were significantly higher in tumor cells than in control 
cells, but MMP-2 expression rate was not. Furthermore, a signif-
icant association was observed between TIMP-1 expression in 
stroma and MMP-13 expression in tumor cells (P=0.013).
Pathologic findings and the expression of MMPs and TIMPs 
Patients were divided by T-stage into early (T1, T2) and advanced 
(T3, T4) stages, and by N-stage into N0 and N+ stages. Relation-
ships between MMP and TIMP expressions in these groups were 
analyzed. It was found that MMP-13 expression in tumor cells 
was significantly correlated with advanced T stage, and MMP-9 
expression in tumor cells and TIMP-1 expression in stroma were 
found to be significantly related to the presence of cervical nod-
al metastasis (Table 2). 
 However, the expressional patterns of MMPs and TIMPs show-
ed no significant correlation with tumor grade, perineural inva-
sion, lymphovascular tumor emboli, or extracapsular extension 
of metastatic lymph nodes. 
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Recurrence and the expressions of MMPs and TIMPs
Clinical follow-up was performed on all 44 patients; one patient 
was lost to follow-up. Three cases (7%) developed local recurren-
ce, 1 (2%) developed cervical nodal recurrence, and in 7 (16%) 
cases developed distant metastasis. 33 of the 44 cases (75%) did 
not recur over >5 years of follow-up. MMP and TIMP expres-
sions showed no significant correlation with primary or regional 
recurrence or distant metastasis. 
Survival and the expressions of MMPs and TIMPs
Of the 44 patients, 31 (70%) remained alive with no evidence 
of disease at the end of the study. Eight patients (18%) died due 
to treatment failure and 5 (11%) died due to other disease with-
out recurrence. The 5-year overall survival rate as determined by 
Kaplan-Meier analysis was 68.18% (Fig. 2). Those expressing 
MMP-9 in tumor cells had significantly poorer survival (Fig. 3), 
but other MMPs or TIMPs positivity in tumor cells was not 
found to be significantly associated with survival. Multivariate 
analysis performed using Cox’s regression test showed that 
MMP-9 expression was significantly associated with survival of 
tonsil SCC patients (hazards ratio, 3.853; confidence interval, 
1.331 to 11.156; P=0.013) (Table 3). 
DISCUSSION
Metastases from head and neck squamous cell carcinoma devel-
op in a step-wise manner, that is, transformed keratinocytes ad-
here to and breakdown basement membrane (BM), and then 
tumor cells infiltrate peripheral tissues. When primary tumor 
grows to a certain size, their survival is threatened because nu-
trient supply by diffusion process alone is inadequate. Thus, tu-
mors may utilize cytokines and other factors to induce angio-
genesis to secure a nutrient supply. Metastasis is another mecha-
nism that allows tumor cells to proliferate, after breaching the 
BM, tumor cells enter into vessels and lymphatic ducts and ad-
here to the endothelial surfaces of other organs. Accordingly, 
proteolytic enzymes probably play a key role in the process that 
leads to metastasis, and the matrix metalloproteinases (MMPs) 
are archetypical proteolytic enzymes (4-6).
 More than 30 types of MMPs have been identified and classi-
fied as: collagenases, gelatinases, stromelysines, stromelysine-
like MMPs, membranous MMPs, and TIMPs. Furthermore, sev-
eral studies have reported that MMP-2, 3, 7, 9, 11, and 13, MT1-
Table 1. Expression rates of MMPs and TIMPs by immunohistochemical staining in squamous cell carcinoma of the tonsil and normal con trol 
tissues (n=45)
MMP-2 MMP-9 MMP-13 TIMP-1 TIMP-2
Negative 24 (53.3) 31 (68.9) 18 (40.0) 25 (55.6) 28 (62.2)
Tumor cell   8 (17.7) 14 (31.1) 13 (28.9) 13 (28.9) 13 (28.9)
Stroma 18 (40.0) - 21 (46.7) 10 (22.2) 11 (24.4)
Tumor & stroma   5 (11.1) -   7 (15.6) 3 (6.7)   7 (15.6)
Normal control   4 (20.0) 0 0 0 0
   (n=20) (P=0.8312) (P=0.0048) (P=0.0072) (P=0.007) (P=0.007)
Values are presented as number (%). Chi-square test.
MMP: matrix metalloproteinase; TIMP: tissue inhibitors of metalloproteinases.
Table 2. Comparative analysis findings for correlations between ex-
pression profiles of MMPs and TIMPs and clinical parameters 
Advanced stage (T3, 4) Nodal metastasis (N+)
Expression rate P-value Expression rate P-value
MMP-2(t) T1, T2 (6/36, 17%) 0.704 N(-) (2/12, 17%) 0.909
T3, T4 (2/9, 22%) N(+) (6/33, 18%)
MMP-2(s) T1, T2 (14/36, 39%) 0.767 N(-) (3/12, 25%) 0.225
T3, T4 (4/9, 44%) N(+) (15/33, 45%)
MMP-9(t) T1, T2 (9/36, 25%) 0.080 N(-) (1/12, 8%) 0.048
T3, T4 (5/9, 56%) N(+) (13/33, 39%)
MMP-13(t) T1, T2 (8/36, 22%) 0.050 N(-) (2/12, 17%) 0.286
T3, T4 (5/9, 56%) N(+) (11/33, 33%)
MMP-13(s) T1, T2 (16/36, 44%) 0.561 N(-) (3/12, 25%) 0.082
T3, T4 (5/9, 56%) N(+) (18/33, 55%)
TIMP-1(t) T1, T2 (11/36, 31%) 0.631 N(-) (4/12, 33%) 0.700
T3, T4 (2/9, 22%) N(+) (9/33, 27%)
TIMP-1(s) T1, T2 (8/36, 22%) 1.000 N(-) (0/12, 0%) 0.031
T3, T4 (2/9, 22%) N(+) (10/33, 30%)
TIMP-2(t) T1, T2 (10/36, 28%) 0.749 N(-) (4/12, 33%) 0.700
T3, T4 (3/9, 33%) N(+) (9/33, 27%)
TIMP-2(s) T1, T2 (11/36, 31%) 0.058 N(-) (2/12, 17%) 0.475
T3, T4 (0/9, 0%) N(+) (9/33, 27%)
Spearman’s correlation analysis.
MMP: matrix metalloproteinase; TIMP: tissue inhibitors of metalloprotein-
ase; t: tumor; s: stroma.
Table 3. Multivariate analysis for factors influencing survival using 
Cox’s regression test 
Wald P-value
MMP-9 6.183 0.013
MMP-13 1.917 0.166
TIMP-1 0.908 0.341
T-stage 1.840 0.175
N-stage 1.358 0.244
MMP: matrix metalloproteinase; TIMP: tissue inhibitors of metalloprotein-
ase.
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MMP, and TIMP-1 contributes functionally to squamous cell car-
cinoma of the head and neck (2).
 MMP-2 is a gelatinase, and has been associated with local in-
vasiveness, cervical nodal metastasis, and the prognosis of oral 
HNSCC. Patel et al. (7) reported that tumor cells obtained from 
39 oral cancer patients showed higher MMP-2 activity than nor-
Fig. 1. Immunohistochemistry in squamous cell carcinoma of the tonsil. Matrix metalloproteinase (MMP)-2 and 13 and tissue inhibitors of metal-
loproteinase (TIMP)-1 and 2 immunostaining were observed in tumor cells and/or stroma but MMP-9 immunostaining was observed in tumor 
cells only (×400). (A) MMP-2 immunostaining in tumor cells. (B) MMP-2 immunostaining in stroma. (C) MMP-9 immunostaining in tumor cells. 
(D) MMP-13 immunostaining in tumor cells. (E) MMP-13 immunostaining in stroma. (F) TIMP-1 immunostaining in tumor cells. (continued to the 
next page).
A B
C D
E F
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Fig. 1. (continued frome the previous page) (G) TIMP-1 immunos-
taining in stroma. (H) TIMP-2 immunostaining in tumor cells. (I) TIMP-
2 immunostaining in stroma.
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I
Fig. 2. Overall 5-year survival of tonsillar squamous cell carcinoma 
patients (n=44).
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mal peripheral cells by zymography, and that MMP-2 activity 
was higher in patients with cervical nodal metastasis than in those 
without. They also reported that MMP-2 activity could be used 
as a predictor future cervical nodal metastasis. Xie et al. (8) re-
ported that the tumors of 32 supraglottic cancer patients showed 
more MMP-2 expression than normal tissues by RT-PCR and 
Fig. 3. Kaplan-Meier curves for tonsillar squamous cell carcinoma 
with respect to matrix metalloproteinase (MMP)-9 expression in tis-
sues.
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immunohistochemistry (IHC), and that MMP-2 was associated 
with the development of cervical nodal metastasis. In addition 
to those of MMP-7 and 9, MMP-2 expression was also found to 
be an indicator of future occult metastasis. Gorogh et al. (9) af-
ter performing RT-PCR, IHC, and zymography on tumor cells 
from 48 laryngeal cancer patients and on 10 types of head and 
neck squamous cell carcinomas (HNSCC) cell lines, concluded 
that MMP-2 expression is associated with the development of 
cervical nodal metastasis. However, Charous et al. (3) found no 
relationship between MMP-2, 9 expression (as determined by in 
situ hybridization) and stage or prognosis among 27 HNSCC 
patients. Furthermore, Burian et al. (10) found no association 
between MMP-2 expression (by IHC) and tumor stage or sur-
vival among 41 patients with laryngeal cancer. In the present 
study, no significant difference was found between tumor and 
normal cells in terms of MMP-2 expression, and no relationship 
between MMP-2 expression and local invasiveness, cervical 
nodal metastasis, recurrence, or survival. Thus, it would be ex-
pected that the role of MMP-2 in tonsil SCC is minimal. How-
ever, more zymographic studies are required to prove this ex-
pectation. Furthermore, it has not been determined whether 
MMP-2 expression originates from tumor cells or peripheral tis-
sues (11, 12). In the present study, cases were observed that ex-
pressed MMP-2 in tumor cells alone or in stromal cells.
 MMP-9 is a gelatinase like MMP-2, but unlike MMP-2, it is 
known that MMP-9 is produced by tumor cells and that its ex-
pression is related to tumor progression and prognosis in several 
HNSCCs. Katayama et al. (13) found that MMP-9 expression in 
tumor cells (as determined by IHC) was significantly associated 
with cervical nodal metastasis and distant metastasis among 53 
patients with early oral cancer, and they also found a significant 
relationship between MMP-9 expression and survival by univar-
iate analysis. O-Charoenrat et al. (14) described that tumor tis-
sues from 54 HNSCC cases showed more MMP-9 expression 
than normal tissues by RT-PCR, Western blot, and zymography 
and that MMP-9 expression was found to be related to T-stage, 
and the presence of cervical nodal metastasis and tumor inva-
sion. Dunne et al. (15) reported that MMP-9 expression in tu-
mor cells (determined by IHC) is statistically associated with T 
stage and cervical nodal metastasis in 105 patients with oropha-
ryngeal SCC. However, Guttman et al. (16) reported that in 23 
patients with tongue SCC, MMP-9 expression in tumor cells 
(determined by IHC) was not related to local invasion, cervical 
nodal metastasis, or survival. In the present study, MMP-9 ex-
pression was detected in tumor cells alone, which suggests that 
MMP-9 is produced by tumor cells. However, we found no sig-
nificant association between MMP-9 expression and T-stage. Ne-
vertheless, MMP-9 tended to be expressed in advanced T-stage 
tumors, and cases with cervical nodal metastasis showed signifi-
cantly more MMP-9 expression than cases without cervical nod-
al metastasis. Furthermore, multivariate analysis showed that 
MMP-9 expression was associated with a poor prognosis, which 
suggests that MMP-9 plays an important role during the tumor 
progression and that its expression likely to be associated with 
survival in tonsil SCC patients who received surgery as initial 
treatment. Multivariate analysis did not show the relationship 
between tumor stage and survival. We thought that the reason 
for this might be due to a relatively small sample size.
 The study of MMP-13 (a collagenase) began only comparative-
ly recently, but nevertheless, considerable work has been con-
ducted on the involvement of MMP-13 in HNSCC. Cazorla et 
al. (17) reported detecting MMP-13 in only tumor tissues by 
Northern and Western blotting in 35 cases with SCC of the lar-
ynx. In addition, they found that MMP-13 expression was asso-
ciated with tumor invasion and differentiation, and that was re-
lated to the overexpressions of MMP-2 and MT1-MMP. Johas-
son et al. (18) in an in situ hybridization study, found that MMP-
13 expression was mainly detected in tumor cells, but that MMP-
13 was also detected in stroma. Furthermore, they reported an 
association between MMP-13 expression and tumor invasion. 
According to our findings, MMP-13, like MMP-2, was detected 
in stroma and in tumor cells. Although no association was found 
between MMP-13 expression and cervical nodal metastasis or 
between it and survival, MMP-13 expression was detected sig-
nificantly more in those with an advanced T-stage. These results 
suggest that MMP-13 may participate in tumor invasion.
 The role of TIMPs in HNSCC is uncertain, though it is assumed 
that TIMPs inhibit the progression of head and neck cancer, be-
cause they suppress MMP (2). Ikebe et al. (19) found that TIMP-
1 levels were high in oral cancer patients without metastasis in a 
57 case study. Gorogh et al. (9) reported that TIMP-1 and 2 lev-
els were inversely related to the occurrence of cervical nodal 
metastasis. However, O-Charoenrat et al. (14) found that TIMP-
1 expression was significantly associated advanced stage of pri-
mary tumor lesions. In the present study, expressions of TIMP-1 
and TIMP-2 were found in tumor tissue alone, and mixed pat-
terns of expression were observed in tumor cell and stroma in 
tumor tissue. Furthermore, TIMP-1 expression in stroma was 
found to be significantly associated with MMP-13 expression in 
tumor cells, and TIMP-1 expression was significantly higher ex-
pression in those with cervical nodal metastasis. However, no 
relationship was found between TIMP expression and recurrence 
or prognosis.
 Studies that have addressed the expressions of MMPs in HN-
SCC have produced inconsistent results, presumably because of 
the various primary sites examined and the many methods used. 
Furthermore, these discrepancies are probably responsible for 
the different opinions expressed regarding the role of MMPs. The 
present study is the first to examine the expressions of MMPs in 
SCC of the tonsil received surgery as initial treatment. We chose 
to use IHC because it has been used most frequently in similar 
studies. In the present study, MMP-9, MMP-13, and TIMP-1 were 
found to be associated with tumor invasion and cervical nodal 
metastasis. Furthermore, multivariate analysis showed that MMP-
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9 is an independent factor that influences survival rate. These re-
sults suggest that MMP-9 could be used as a prognostic indicator 
of tonsil cancer patients who received surgery as initial treatment.
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